ESTRO 2024 - Abstract Book

S402

Brachytherapy - Urology

ESTRO 2024

24 patients received salvage LDR brachytherapy. The median age was 65. The median follow-up was 57 months. The median time from completion of external beam radiotherapy to LDR brachytherapy was 86 months. All patients had a biopsy proven recurrence and all had an MRI pelvis and bone scan prior to proceeding with brachytherapy. All patients were prescribed a dose of 120Gy. Acute and late gastrointestinal (GI) toxicities were observed in 6/24(25%) and 14/24(58%) of the cohort respectively. There were no observed grade 3 or higher GI toxicities. Acute grade 1, 2 and 3 genitourinary(GU) toxicity was reported in 10/24(42%), 8/24(33%) and 3/24(12%) respectively. Late grade 1, 2 and 3 GU toxicity was reported in 7/24 (29%), 15/24(62%) and 1/24(4%) respectively. The median biochemical-recurrence free survival, androgen-deprivation-therapy free survival, radiological-progression free survival and overall survival were 42 months, 76 months, 108 months and 115 months respectively.

Conclusion:

LDR brachytherapy is a safe and effective salvage treatment option for locally recurrent prostate cancer.

Keywords: Salvage, LDR, Brachytherapy

649

Poster Discussion

HDR brachytherapy as monotherapy in the treatment of prostate cancer

Oxana Komina 1 , Christine Seitz-Kästner 1 , Thomas Pajer 1 , Bettina Kohl 1 , Johann Hummel 2 , Tomas-Hendrik Knocke Abulesz 1 , Elisabeth Nechvile 1 1 Klinik Hietzing, Sonderabteilung für Strahlentherapie, Vienna, Austria. 2 AKH Wien, Zentrum für Medizinische Physik und Biomedizinische Technik, Vienna, Austria

Purpose/Objective:

Radiotherapy (RT) plays a critical role in the treatment of prostate cancer. The efficacy of high dose rate brachytherapy (HDR-BT) as a monotherapy in terms of a highly conformal technique that allows high fractional doses to be delivered to the tumor with very good sparing of organs at risk (OAR) has been demonstrated in several clinical trials.

Material/Methods:

We summarized the data of those patients treated in our institution since implementation of the real-time planning system based on 3D ultrasound imaging since 2010. In total, 258 patients with localized disease received HDR-BT as monotherapy (4 x 9 Gy [n=17], 3 x 10.5 Gy [n=241] from 2012, BED 252 Gy, calculating with α/β ratio of 1.5) between 01/2010 and 12/2021. Gastrointestinal (GI) and urogenital (GU) acute and late toxicities were documented according to RTOG/EORTC criteria. Biochemical control was recorded according to Phoenix definition.